Friday, 21 Sep 2018

You are here

Inflammatory Arthritis Variants with Checkpoint Inhibitors

Two recently published studies have demonstrated distinctive patterns of rheumatic complaints in patients treated wtih immune checkpoint inhibitors (ICIs).

Capelli and colleagues have studied patients treated with ICIs and found two variants of inflammatory arthritis (IA) - a reactive arthritis like large joint arthritis with combination ICI therapy or a small joint IA with ICI monotherapy.

Inflammatory arthritis (IA) is of several immune-related adverse event (irAE) seen with ICI therapy.

They identified 30 patients with combination ICI therapy who primarily presented with knee arthritis, with high C-reactive protein levels, a prior irAE, and show a a reactive arthritis-like phenotype.

By contrast, those treated with ICI monotherapy were more likely to have initial small joint involvement and to have IA as their only irAE.

Ten patients required additional immunosuppression beyond corticosteroids, with TNF-inhibitors and/or methotrexate. Those on TNF inhibitors did not show tumor progression.

Another French cohort study described the two rheumatic variants in 35 (6.6%) of their 524 ICI treated patients. (Citation source: https://buff.ly/2HV9msa)

All but one of the rheumatic irAEs occurred with anti-programmed cell death protein 1(PD-1)/PD-1 ligand 1(PD-L1) antibodies, with a median exposure time of 70 days.

Patients either exhibited IA that mimicked rheumatoid arthritis (n=7), polymyalgia rheumatica (n=11) or psoriatic arthritis (n=2) or they demonstrated non-inflammatory musculoskeletal conditions (2.8%; n=15).

IA patients required glucocorticoids, and methotrexate was started in two patients.

Non-inflammatory disorders were managed with non-steroidal anti-inflammatory drugs, analgesics and/or physiotherapy.

They noted that those with rheumatic irAEs had a higher tumour response rate compared with patients without irAEs (85.7% vs 35.3%; P<0.0001).

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

More Like This

New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis

The British Society of Rheumatology has produced a set of NICE accredited guidelines for the use of biologic therapies in patients with inflammatory arthritis.

It addresses safety recommendations for all biologic therapies approved by the National Institute for Health and Care Excellence (NICE) up to June 2016, for use in all inflammatory arthritides [RA, PsA and axial SpA (SpA) including AS].

The Safety of Paternal Exposure to DMARDs and Biologics

Pregnancy and drug safety is a complex issue, often with limited informatoin about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.

A systematic review examined the effect of disease modifying anti-rheumatic drugs (DMARDs) on male fertility and if peri-conception (within 3 months) paternal exposure was detrimental to fetal outcomes.

2018-2019 ACIP Recommendations for Seasonal Influenza Vaccination

The current issue of the CDC's MMWR reviews the new seasonal recommendations for vaccination against influenza. This is an update to the previous recommendations of the Advisory Committee on Immunization Practices (ACIP). 

Health Secretary Azar Eyes Rebate Reform

Reuters reports that the U.S. Health and Human Services Secretary Alex Azar had declared his agency has the authority to eliminate rebates on prescription drug purchases, a key element in the administration’s plan to lower prescription medicine costs.

Azar has said rebates created a perverse incentive to continuously raise drug prices.

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).